- <![CDATA[FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease]]><![CDATA[The FDA and Atara Biotherapeutics completed a Type A meeting to discuss the CRL for tabelecleucel in post-transplant lymphoproliferative disease.]]>onclive · 2mo ago↗ source
- <![CDATA[ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies]]><![CDATA[Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting. ]]>onclive · 2mo ago↗ source
- Angelini to buy Catalyst in $4B play for rare neuro drugs<figure><div><img src="https://imgproxy.divecdn.com/4_eQ3BQP0sHe3AjR5s7bySznoaDhyqMpmhkmNubOdkU/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDQwMTY4MDMyXzEua…